Zydus Lifesciences and MSN Laboratories Launch First Generic Adempas in US
Zydus Lifesciences and MSN Laboratories have launched the first generic version of Adempas (Riociguat tablets) in the US, approved by the USFDA in five strengths. Riociguat treats adults with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. The companies highlighted this as a milestone reflecting their capabilities in complex generics. Bayer's 2025 report cited global Adempas sales at approximately USD 850 million.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 41/100.
Outlets measured: english, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 5 Oct, 07:17 pm. Other outlets followed.
- 1